Bomedemstat

• Description:

  Bomedemstat (IMG-7289) is an orally active and irreversible lysine-specific demethylase 1 (LSD1) inhibitor. Bomedemstat can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis[1][2].

• Product Name Alternative:

  IMG-7289

• UNSPSC:

  12352005

• Target:

  Apoptosis; Histone Demethylase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bomedemstat.html

• Purity:

  99.55

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O=C (N1CCN (CC1) C) [C@@H] (NC (C2=CC=C (N3C=CN=N3) C=C2) =O) CCCN[C@H]4[C@@] (C5=CC=C (C=C5) F) ([H]) C4

• Molecular Formula:

  C28H34FN7O2

• Molecular Weight:

  519.61

• References & Citations:

  [1]Jonas S Jutzi, et al. LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone. Hemasphere.2018 Jun 8;2 (3) :e54. |[2]Yuan Fang, et al. LSD1/KDM1A inhibitors in clinical trials: advances and prospects. J Hematol Oncol. 2019 Dec 4;12 (1) :129.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 3

• Isoform:

  KDM1/LSD1

• CAS Number:

  1990504-34-1